{"nctId":"NCT01801735","briefTitle":"Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip","startDateStruct":{"date":"2013-03"},"conditions":["Osteoarthritis"],"count":600,"armGroups":[{"label":"Meloxicam Test Capsules","type":"EXPERIMENTAL","interventionNames":["Drug: Meloxicam Test Capsules"]}],"interventions":[{"name":"Meloxicam Test Capsules","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is male or female â‰¥ 40 years of age\n* If a participant in the previous MEL3-12-02 study, completed the study and did not discontinue for lack of efficacy or safety\n* Has a diagnosis of OA of the hip or knee with ongoing knee and/or articular hip pain\n* Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain\n* If female and of childbearing potential, is nonlactating and nonpregnant\n\nExclusion Criteria:\n\n* History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam\n* Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip\n* Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease\n* Significant difficulties swallowing capsules or unable to tolerate oral medication\n* Has received any investigational drug (except Meloxicam SoluMatrix Capsules), device, or therapy within 30 days before Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination","description":"The safety of Meloxicam 10 mg was assessed by the number of subjects with treatment-emergent adverse events (TEAEs), severe TEAEs, serious adverse events, treatment-related TEAEs, and adverse events (AEs) leading to discontinuation and subjects who died.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"406","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":600},"commonTop":["Arthralgia","Urinary tract infection"]}}}